2023-507868-39-00招募中4 期
Evaluating, clinical and immunological effects of rituximab with cyclophosphamide compared to rituximab alone in AAV patients (The ENDURRANCE-1 Study)
试验速览
- 阶段
- 4 期
- 状态
- 招募中
- 入组人数
- 100
- 试验地点
- 8
- 主要终点
- Compare the number of RTX retreatment infusions needed to maintain clinical remission over 2 years, based on B-cell status and ANCA status, in both arms
研究概览
简要总结
The primary objective is the number of RTX infusions needed to maintain clinical remission over 2 years
入排标准
- 年龄范围
- 18 years 至 65+ years（65+ Years, 18-64 Years）
- 接受健康志愿者
- 否
入选标准
- •Clinical diagnosis of granulomatosis with polyangiitis (GPA) or microscopic Polyangiitis (MPA), consistent with Chapel-Hill Consensus Conference definitions
- •Aged at least 18 years, with newly-diagnosed or relapsed AAV with ‘generalised disease’, defined as involvement of at least one major organ (e.g. kidney, lung, heart, peripheral or central nervous system), requiring induction treatment with cyclophosphamide or rituximab
- •Positive test for anti-PR3 or anti-MPO (current or historic)
- •Willing and able to give written Informed Consent and to comply with the requirements of the study protocol
排除标准
- •Pregnant or breast-feeding
- •Required dialysis or plasma exchange within 12 weeks prior to screening
- •Received intravenous glucocorticoids, >3000mg methylprednisolone equivalent, within 4 weeks prior to screening
- •Immunization with a live vaccine 1 month before screening
- •History or presence of any medical condition or disease which, in the opinion of the Investigator, may place the patient at unacceptable risk for study participation
- •Have a history of an anaphylactic reaction to parenteral administration of contrast agents, human or murine proteins or monoclonal antibodies
- •Active pregnancy, as proven by a positive urine beta-HCG test or a positive serum beta-HCG
- •Significant hypogammaglobulinemia (IgG < 4.0 g/L) or an IgA deficiency (IgA < 0.1 g/L)
- •Active infection not compatible with start of remission-induction therapy in the opinion of the treating physician and/or investigator, e.g.: - Serological evidence of viral hepatitis defined as: patients positive for HbsAg test or HBcAb or a positive hepatitis C antibody not treated with antiviral medication - Have a historically positive HIV test or test positive at screening for HIV
- •Have a history of a primary immunodeficiency
- •Have a significant infection history that in the opinion of the investigator would make the candidate unsuitable for the study
- •Have a neutrophil count of < 1.5x10E9/L
- •Evidence of hepatic disease: AST, ALT, alkaline phosphatase, or bilirubin > 3 times the upper limit of normal before start of dosing
- •Have any other clinically significant abnormal laboratory value in the opinion of the investigator
结局指标
主要结局
Compare the number of RTX retreatment infusions needed to maintain clinical remission over 2 years, based on B-cell status and ANCA status, in both arms
Compare the number of RTX retreatment infusions needed to maintain clinical remission over 2 years, based on B-cell status and ANCA status, in both arms
次要结局
- To assess clinical disease activity of each treatment arm as described in section 7.2.3 of the protocol
- To assess the safety parameters of each treatment arm including adverse events according to WHO toxicity criteria and recording of infectious events
- Assess the time to an ANCA negative test by using a high-quality ELISA measuring ANCAs. A negative test is defined as below the detection level
- Assess the time to ANCA return defined as seroconversion to positive on at least 2 consecutive visits (the time of the first is then representative time of seroconversion) OR a doubling of the ANCA serum levels PR3 or MPO ELISA test compared to a previously achieved nadir
- Duration of B-cell depletion defined as time taken to detect a repopulation of B-cells above the detection limit of standard flowcytometry (i.e. > 1x10^6 cells/L)
- To assess quality of life by patient related outcome scores (AAV-PRO and SNOT22)
研究者
Y.K.O. Teng
Scientific
Academisch Ziekenhuis Leiden
研究点 (8)
Loading locations...
相似试验
招募中
2 期
Evaluation of the efficacy and safety of Rituximab in patients with Amyotrophic Lateral Sclerosis (ALS)2022-502743-35-00Deutsches Zentrum Fuer Neurodegenerative Erkrankungen e.V.52
招募中
2 期
A Phase II Study to Evaluate the Efficacy and Safety of HLX43 + Serplulimab as Neoadjuvant Therapy in Subjects With NSCLCNCT07269782Shanghai Henlius Biotech60
招募中
3 期
First-line immunotherapy-based standard of care and local ablative treatments for oligometastatic non-small cell lung cancer patients: a randomized, multicentre, open-label phase III study (OliGRAIL)2023-503326-39-00Institut Gustave Roussy130
招募中
3 期
Rituximab-induced remission in CIDP (ReCIX study)2024-512506-25-00Amsterdam UMC Stichting102
招募中
2 期
A Phase II study evaluating efficacy of KTE-X19 CAR-T cell therapy in Relapsed or Refractory Mantle-Cell Lymphoma achieving a partial response during Ibrutinib salvage therapy2022-502907-31-00Fondazione IRCCS Istituto Nazionale Dei Tumori20